

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
26 June 2025 (26.06.2025)



(10) International Publication Number
WO 2025/136986 A3

(51) International Patent Classification:
C07K 14/54 (2006.01) A61P 35/00 (2006.01)
A61K 38/17 (2006.01)

SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:
PCT/US2024/060580

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))

(22) International Filing Date:
17 December 2024 (17.12.2024)

(25) Filing Language: English

(26) Publication Language: English

(88) Date of publication of the international search report:
24 July 2025 (24.07.2025)

(30) Priority Data:
63/611,673 18 December 2023 (18.12.2023) US

(71) Applicant: GENZYME CORPORATION [US/US]; 450
Water Street, Cambridge, Massachusetts 02141 (US).

(72) Inventors: LHUILLIER, Claire; c/o Genzyme Corpora-
tion, 450 Water Street, Cambridge, Massachusetts 02141
(US). BEIL, Christian; c/o Genzyme Corporation, 450
Water Street, Cambridge, Massachusetts 02141 (US).
AMENGUAL RIGO, José Antonio; c/o Genzyme Corpo-
ration, 450 Water Street, Cambridge, Massachusetts 02141
(US). QIU, Yu; c/o Genzyme Corporation, 450 Water
Street, Cambridge, Massachusetts 021241 (US). LI, Xiang-
ming; c/o Genzyme Corporation, 450 Water Street, Cam-
bridge, Massachusetts 02141 (US).

(74) Agent: VELEMA, James H. et al.; LATHROP GPM LLP,
28 State Street, Boston, Massachusetts 02109 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,

(54) Title: IL-12 LOSS OF POTENCY MUTEINS

(57) Abstract: The present invention provides pharmaceutical compositions comprising IL-12 muteins, isolated nucleic acids encoding the muteins, vectors, and host cells containing the same, and methods or uses of such compositions for the treatment of a disease or disorder.

WO 2025/136986 A3